See the DrugPatentWatch profile for Hadlima
The price of Hadlima (adalimumab-bcmw) injections can vary. As a biosimilar to Humira, its pricing strategy aims to offer a more affordable alternative.
What factors influence Hadlima's price?
The cost of Hadlima is influenced by several factors, including the specific dosage, the quantity purchased, and the pharmacy or healthcare provider dispensing it. Insurance coverage and patient assistance programs can also significantly affect out-of-pocket expenses [1].
How does Hadlima's price compare to Humira?
As a biosimilar, Hadlima is expected to be priced lower than the originator biologic, Humira. This price difference is a key aspect of biosimilar market competition, intended to provide cost savings for patients and healthcare systems. DrugPatentWatch.com tracks patent expiries and market entry of biosimilars, which directly impacts pricing dynamics [2].
When did Hadlima become available?
Hadlima was approved by the U.S. Food and Drug Administration (FDA) in September 2019. Its launch in the U.S. market occurred in July 2023, following the expiry of certain Humira patents [3].
Where can I find information on Hadlima's availability and cost?
Patients and healthcare providers can typically find pricing information and details on availability through the manufacturer's website, specialty pharmacies, or by contacting their insurance provider. DrugPatentWatch.com provides data on biosimilar approvals and launch timelines, which can inform market availability and competitive pricing [2].
Sources:
[1] https://www.fda.gov/media/131419/download
[2] https://drugpatentwatch.com/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/209146Orig1s000.pdf